Xeris Biopharma Holdings (XERS) Liabilities and Shareholders Equity (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $392.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 24.27% year-over-year to $392.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 14.64% YoY) and the FY2025 annual result came in at $383.5 million, up 18.72% from the prior year.
• Liabilities and Shareholders Equity rose to $392.0 million in Q1 2026, from $383.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $392.0 million in Q1 2026 to a low of $303.0 million in Q3 2022.
• A 5-year average of $336.0 million and a median of $328.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 130.85% — and 2023, when it declined 6.36%.
• Tracing XERS's Liabilities and Shareholders Equity over 5 years: stood at $344.5 million in 2022, then decreased by 6.36% to $322.6 million in 2023, then climbed by 0.14% to $323.1 million in 2024, then climbed by 18.72% to $383.5 million in 2025, then grew by 2.21% to $392.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $392.0 million (Q1 2026), $383.5 million (Q4 2025), and $370.2 million (Q3 2025), per Business Quant data.